EPS (TTM) and P/E are suppressed: a stock split falls inside the trailing-four-quarter window, and SEC facts keep only the latest-filed value, so the as-filed quarterly EPS prints mix pre- and post-split bases — no single-basis trailing EPS exists to sum.
Cash-flow figures use the latest fiscal year: this filer tags quarterly cash flows year-to-date only and the missing discrete quarters could not be derived (irregular fiscal quarters or a tagging change), so no four consecutive quarters exist to sum.
full derived coverage requires a plan
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
— Months · distinct values (the real sample size).
Metric
Today
Own median
Own range
%ile
z
Sector med.
mo · distinct
P/E
—
P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
−224.1% (2025-02)
—
no band (36 mo · 3 distinct)
—
—
−36.9%
36 · 3
ROIC
—
no reconstructed observations for this name and metric.
−50.3%
−292.3%
no band (54 mo · 5 distinct)
—
—
−21.3%
54 · 5
−32.7%
−17.3%
69th
+0.48σ
5.1%
89 · 89
EPS Growth 3Y
—
P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
57.9%
—
no band (18 mo · 2 distinct)
—
—
9.0%
18 · 2
Market Cap
$80.40M
not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series.
ROE (point-in-time)Health Care median, same monthshaded = own p25–p75
Multiple-implied price ladder · Full
Filed earnings only.
no P/E ladder — P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Ladder not drawn for this name — the reason is above.ⓘ
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Percentile through time (point-in-time cohort)
Loading the monthly cohort placement…
▸Comp setname your own peers — pick a pool or add tickers
Growth, restated as sharewhere each pace has to END UP, by 2030
Its own realised pace0.0% → 0.0%
The pace the price requires— The growth today's price requires (our reverse-DCF) is a Pro metric — the realized-pace runway above is free.
VRCA share over time5 published years
Calendar year
2021
2022
2023
2024
2025
Share of covered pool
0.0%
0.0%
0.0%
0.0%
0.0%
share_5y: this company has no 2020… · coverage: 321 of the 385 members that…
Share of covered industry revenue · n=348 in Pharmaceuticals & Biotechnology · CY2025 pool · built 2026-08-20 not market shareⓘ
Covered filers only, not market share — private and uncovered companies are missing, so every share here reads high. Years are FX-converted and published only once most of the pool has filed.
